BioSpace News Archive

Drug Development

Vaccine Manufacturers Race to Beat Wild Card COVID-19 Mutations

Vaccine makers are working to create boosters or modify their existing vaccines to better respond to the variants.

April 9, 2021
·
5 min read
·
Mark Terry
Policy

Fraudsters Posing as Biotech Companies Seek to Capitalize on COVID-19 Panic

The fear caused by COVID-19 provides an “in” for fraudsters to exploit thousands of Americans by posing as biotech companies.

April 9, 2021
·
2 min read
·
Alexandra Schwier
Drug Development

Clinical Catch-Up: April 5-9

It was a relatively quiet week for clinical trial announcements, but there were a few standouts. Read on for more.

April 9, 2021
·
6 min read
·
Mark Terry
Drug Development

Bristol Myers Squibb’s Opdivo Combos Superior in Esophageal Cancer

Bristol Myers Squibb announced topline data from the Phase III CheckMate -648 trial on Thursday, with positive results in esophageal cancer.

April 9, 2021
·
2 min read
·
Mark Terry
BioForest

Companies Showcase Data in Multiple Cancers Ahead of 2021 Virtual AACR Meeting

Data on multiple oncology therapeutic programs are being unveiled ahead of the start of the annual American Association for Cancer Research meeting, which will be held virtually this year due to the ongoing COVID-19 pandemic.

April 9, 2021
·
5 min read
·
Alex Keown
How a Common Cold Virus is Helping Fight Cancer

While a failed ebola drug helped treat hospitalized COVID-19 patients, the common cold virus could become key in treating advanced unresectable cancers.

April 9, 2021
·
2 min read
·
Kate Goodwin
Biotech Bay

COVID-19 News: Clinical Trial for Moderna Booster Begins and More

There continue to be studies and trials related to vaccines and drugs against COVID-19. Here’s a look.

April 9, 2021
·
3 min read
·
Mark Terry
Business

Celcuity and Pfizer Enter Agreement for Breast Cancer Drug Following Positive Data

Clinical-stage biotech company Celcuity announced Thursday that it had entered into a global licensing agreement with Pfizer to develop and commercialize gedatolisib, the latter company’s first-in-class PI3K/mTOR inhibitor for the treatment of breast cancer.

April 9, 2021
·
3 min read
·
Brandon May
FDA

FDA Action Alert: Avenue, Merck, Sol-Gel, Protalix and Chiesi, and Ardelyx

The U.S. Food and Drug Administration’s schedule for April has several PDUFA dates scattered across the rest of the month. Here’s a look.

April 9, 2021
·
4 min read
·
Mark Terry
Deals

Sanofi Snatches Up Tidal Therapeutics in $470 Million Deal

Tidal Therapeutics, which does not even have a website, came out of LabCentral in Cambridge. It focuses on developing nanoparticles able to deliver messenger RNA (mRNA) that can reprogram immune cells.

April 9, 2021
·
3 min read
·
Mark Terry